World Health Organization, Harare, Zimbabwe.
Clinton Health Access Initiative, Harare, Zimbabwe.
Front Public Health. 2022 Jul 19;10:871567. doi: 10.3389/fpubh.2022.871567. eCollection 2022.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spreads rapidly, causing outbreaks that grow exponentially within a short period before interventions are sought and effectively implemented. Testing is part of the first line of defense against Corona Virus Disease of 2019 (COVID-19), playing a critical role in the early identification and isolation of cases to slow transmission, provision of targeted care to those affected, and protection of health system operations. Laboratory tests for COVID-19 based on nucleic acid amplification techniques were rapidly developed in the early days of the pandemic, but such tests typically require sophisticated laboratory infrastructure and skilled staff. In March 2020, Zimbabwe confirmed its first case of COVID-19; this was followed by an increase in infection rates as the pandemic spread across the country, thus increasing the demand for testing. One national laboratory was set to test all the country's COVID-19 suspect cases, building pressure on human and financial resources. Staff burnout and longer turnaround times of more than 48 h were experienced, and results were released late for clinical relevance. Leveraging on existing PCR testing platforms, including GeneXpert machines, eased the pressure for a short period before facing the stockout of SARs-CoV-2 cartridges for a long time, leading to work overload at a few testing sites contributing to long turnaround times. On September 11, WHO released the interim guidance to use antigen rapid diagnostic test as a diagnostic tool. The Zimbabwe laboratory pillar quickly adopted it and made plans for its implementation. The National Microbiology Reference Laboratory verified the two emergency-listed kits, the Panbio Abbott and the Standard Q, Biosensor, and they met the WHO minimum performance of ≥97% specificity and ≥80% sensitivity. Decentralizing diagnostic testing leveraging existing human resources became a game-changer in improving COVID-19 containment measures. Task shifting through training on Antigen rapid diagnostic tests (Ag-RDT) commenced, and testing was decentralized to all the ten provinces, from 1 central testing laboratory to more than 1,000 testing centers. WhatsApp platforms made it easier for data to be reported from remote areas. Result turnaround times were improved to the same day, and accessibility to testing was enhanced.
严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)传播迅速,在采取干预措施并有效实施之前,在短时间内呈指数级增长。检测是针对 2019 年冠状病毒病(COVID-19)的第一道防线的一部分,在早期识别和隔离病例以减缓传播、为受影响者提供有针对性的护理以及保护卫生系统的运作方面发挥着关键作用。基于核酸扩增技术的 COVID-19 实验室检测在大流行早期迅速发展,但此类检测通常需要复杂的实验室基础设施和熟练的工作人员。2020 年 3 月,津巴布韦确认了首例 COVID-19 病例;随着大流行在全国范围内蔓延,感染率上升,对检测的需求也随之增加。一个国家实验室负责检测该国所有 COVID-19 疑似病例,这给人力和财力资源带来了压力。工作人员倦怠和超过 48 小时的周转时间延长,以及结果延迟发布以确保临床相关性。利用现有的 PCR 检测平台,包括 GeneXpert 机器,在一段时间内缓解了压力,然后面临 SARS-CoV-2 试剂盒长期缺货的问题,导致少数检测点的工作负荷过重,导致周转时间延长。9 月 11 日,世卫组织发布了使用抗原快速诊断检测作为诊断工具的临时指南。津巴布韦的实验室支柱部门迅速采用了该指南,并制定了实施计划。国家微生物学参考实验室对两种紧急上市的试剂盒,即 Panbio Abbott 和 Standard Q Biosensor,进行了验证,它们符合世卫组织最低性能要求,特异性≥97%,灵敏度≥80%。利用现有人力资源分散诊断检测成为改善 COVID-19 控制措施的关键。抗原快速诊断检测(Ag-RDT)培训开始了任务转移,检测从一个中央检测实验室分散到了 10 个省份的 1000 多个检测中心。WhatsApp 平台使从偏远地区报告数据变得更加容易。结果周转时间提高到当天,检测的可及性也得到了提高。